LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts UTRECHT,…
CoC Vault Goes Live Ahead of South Africa’s 20 September Trade Deadline
Boba Provides Corporate Update and Arranges Second $250,000 Private Placement
Cathedra Bitcoin Inc. Provides Additional Disclosure Regarding the Series I Preferred Shares Issuable in Connection with Its Plan of Arrangement with Sphere 3D Corp.
eResearch Updates Research Coverage on Turnium Technology Group